OP0006 Safety and efficacy of lenabasum (JBT-101) in diffuse cutaneous systemic sclerosis subjects treated for one year in an open-label extension of trial jbt101-ssc-001 - Spiera, R.; Hummers, L.; Chung, L.; Frech, T.; Domsic, R.; Hsu, V.; Furst, D.E.; Gordon, J.; Mayes, M.; Simms, R.; Lee, E.; Dgetluck, N.; et al. (Annals of the rheumatic diseases, 2018)
Keywords: Animal models; Cannabinoid CB2 receptors; Clinical trials; Diarrhea; Fibrosis; Immune response; Immunosuppressive agents; Innate immunity; Pharmaceuticals; Prednisone; Respiratory tract diseases; Safety; Scleroderma; Skin; Systemic sclerosis; Ulcers; Urinary tract